Navigation Links
Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress
Date:3/15/2008

t the entire one-year treatment period. Significantly fewer serious adverse events were reported in the Dimebon group than in the placebo group at 12 months (p=0.03).

Medivation is planning to initiate a second, confirmatory pivotal Phase 3 trial of Dimebon in mild-to-moderate Alzheimer's disease in the second quarter of 2008 with the goal of completing the trial and applying for U.S. and European marketing approval in 2010. The Company is also evaluating Dimebon in an ongoing Phase 2 clinical trial in mild-to-moderate Huntington's disease. Dimebon is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's and Huntington's diseases, making it a potential treatment for these and other neurodegenerative diseases.

About Medivation

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company's strategy is to identify promising product candidates, to develop them in a rapid, cost-effective manner, and to seek development and/or commercialization partners as appropriate to complement its internal efforts. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding anticipated clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significan
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
2. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
3. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
4. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
5. New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
6. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
7. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 BRIC Gynecological Devices Market Outlook ... GlobalData,s new report, "BRIC Gynecological Devices Market Outlook ... BRIC Gynecological Devices market. The report provides value, ... and average prices (in US dollars) within market ... (Micro-inserts) and Mechanical Sterilization Devices (Tubal Clips and ...
(Date:9/17/2014)... 17, 2014 The ambulance equipment ... decade due to the recession, an unstable ... advancements. This BCC Research report analyzes present ... the ambulance and emergency medical services equipment ... hemorrhage control devices, equipment used for burn ...
(Date:9/17/2014)... Pomerantz LLP is investigating claims on behalf ... the "Company") (NASDAQ: PDLI).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... and/or directors have violated Sections 10(b) and 20(a) of ... On September 17, 2014, the Company announced that On ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2
... 2012 Synteract , Inc., a full-service contract ... developing new therapies to combat the growing issue of ... Great Strides fundraising walk to benefit the Cystic ... Rempex (on behalf of Aptalis Pharma) are also working ...
... Ind., May 2, 2012  Hill-Rom Holdings, Inc. (NYSE: ... declared a fiscal year 2012 third quarter dividend of $0.125 ... to shareholders of record as of the close of business ... HOLDINGS, INC. Hill-Rom is a leading worldwide manufacturer ...
Cached Medicine Technology:Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2
(Date:9/17/2014)... 17, 2014 Final Cut Pro X plugin ... 5k from Pixel Film Studios. , “ProBlue 5k is a ... from good to epic,” said Christina Austin, CEO of Pixel ... 5k is a definite game changer.” , ProBlue 5k is ... any filmmaker ! This footage compilation of over 100 ...
(Date:9/17/2014)... September 17, 2014 People who struggle to ... head to http://www.perwickstrom.com and get the answer by ... to point out, is that a business plan and a ... work together, commented Per Wickstrom. “The way I view it ... a business strategy which is part two.” , According ...
(Date:9/17/2014)... Chicago IL (PRWEB) September 17, 2014 ... of Pseudomonas aeruginosa infections allegedly caused by Non-Sterile ... to learn more about their options for legal recourse. ... & Drug Administration (FDA) in March 2012, after the ... Pseudomonas aeruginosa at William Beaumont Hospital in Royal Oak, ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. ... to household chemicals known as phthalates might increase a ... reported in a new study. Children had nearly ... age 5 and 11 if their mothers were exposed ... thal-ates), the researchers found. The two phthalates were butylbenzyl ...
(Date:9/17/2014)... Texas (PRWEB) September 17, 2014 Prevention ... outbreak that is hospitalizing scores of infants, children and ... says Dr. Kirk Mahon, medical director of Legacy ER ... “There have been no reported cases of EV-D68 so ... and Louisiana, that could change,” he said. “Implementing prevention ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2
... ... ... , , ... ...
... , ... plans to address neighborhood concerns. , ... South Boston, MA (PRWEB) March 1, 2010 -- Fenway Bark today announced operational changes ... before the City of Boston Zoning Board of Appeal, to request an Interim Planning Overlay ...
... ... ... ... ...
... , ... ... ... ...
... ... , ... , , , ... MCKINNEY, ...
... ... , ... , , , , ... ...
Cached Medicine News:Health News:Northstar Management Forecasts a Loss of $1.2 Million for 2010 at Its Palladium for Surgery -- Houston, Ltd. Centre 2Health News:Dog Owners and Southie Residents Welcome Fenway Bark Into the Pack 2Health News:Dog Owners and Southie Residents Welcome Fenway Bark Into the Pack 3Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 2Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 3Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 4Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 5Health News:Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 2Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 3Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 4Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 5Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 6Health News:AMA: Physicians Outraged at Today's Steep Medicare Cut 7Health News:Torchmark Corporation Declares Dividend and Resumes Stock Repurchases 2Health News:MedCath Corporation Announces Decision to Consider Strategic Options 2
Foley Catheters (Latex) 3-Way...
ULTRAMER Foley Catheter...
Coude Foley Catheters (Latex) 2-Way Amber...
Silicone-Coated Foley Catheter 2-Way...
Medicine Products: